Nebivolol
Nebivolol is a beta-blocker taken by mouth. The US label read, for Bystolic, lists one use: the treatment of hypertension, to lower blood pressure.
Also called Bystolic
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 31555; UNII JGS34J7L9I. The label names the substance as nebivolol hydrochloride, so UNII JGS34J7L9I is the UNII of the hydrochloride salt and is a broad match. MeSH descriptor D000068577 is Nebivolol. Class: beta-Adrenergic Blocker (FDA established pharmacologic class, RxClass). The label read is the Allergan, Inc. label for BYSTOLIC (nebivolol hydrochloride), application NDA021742, effective 2024-08-01 in openFDA. Other nebivolol labels in openFDA, from generic sponsors, were not read. This page records label indications and the class only: no trial result and no dose is given.
Trials at a glance
The figures count the 6 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.
- Trials
- 6
- Phase 3 or 4
- 5
- Recruiting
- 1
- Regulatory decisions
- 0
| Phase | Recruiting | Not yet recruiting | Active, not recruiting | Completed | All statuses |
|---|---|---|---|---|---|
| Phase 2/3 | 1 | 0 | 0 | 0 | 1 |
| Phase 4 | 0 | 1 | 1 | 3 | 5 |
| All phases | 1 | 1 | 1 | 3 | 6 |
Conditions these trials study
- Hypertension (high blood pressure)
- Angina pectoris
- Brain aneurysm (intracranial aneurysm)
- Heart attack (myocardial infarction)
- Microvascular and vasospastic angina
- Non-ST-elevation heart attack (NSTEMI)
- ST-elevation heart attack (STEMI)
Sponsors with the most trials
About this drug
- Level
- Substance
- Mechanism
- Not reported
Classification codes
-
JGS34J7L9I
Claims and evidence
Context People for whom the US label of nebivolol (Bystolic) lists an indication: hypertension
- Recipient
- Recipient not specified
- Population
- Patients described in the indications section of the label. The label does not state an age range in the passage read.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the label passage read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Patients with hypertension
- Excluded
- None stated
The US label of BYSTOLIC (nebivolol hydrochloride), in the Allergan, Inc. version dated 2024-08-01 in openFDA, lists the medicine for the treatment of hypertension, to lower blood pressure.
Applies to Recipient not specified People for whom the US label of nebivolol (Bystolic) lists an indication: hypertension
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-08
- Next evidence check due
- Not scheduled
Sources and citations (2)
-
- Locator
- results[0].indications_and_usage[0], 1. INDICATIONS AND USAGE
- How it applies
- The label sentences that give the indications named in the statement, each quoted in the research quote table.
- Retrieved
- Source effective date
- 2024-08-01
- Source state
- Current
- Version fingerprint
272454333965f93512f2cc1866c29f068170de6a24c0b87238d21dba3f07fdef- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-08, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20240801.
- Retrieved
- Source effective date
- 2024-08-01
- Source state
- Current
- Version fingerprint
272454333965f93512f2cc1866c29f068170de6a24c0b87238d21dba3f07fdef- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-08, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
FDA label
The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.
BYSTOLIC
No label from the application holder was found in the openFDA label dataset for application NDA021742. This page does not show another labeler's label in its place.
BYVALSON
No label from the application holder was found in the openFDA label dataset for application NDA206302. This page does not show another labeler's label in its place.
FDA decisions timeline
The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists hypertension as an indication: Hypertension (high blood pressure)
Applies to Recipient not specified People for whom the US label of nebivolol (Bystolic) lists an indication: hypertension
The US label of BYSTOLIC (nebivolol hydrochloride), in the Allergan, Inc. version dated 2024-08-01 in openFDA, lists the medicine for the treatment of hypertension, to lower blood pressure.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry products 2
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
Registry trials 6
Record details
- Record id
cardio:nebivolol- Content hash
df4cc2591bc44831f9e9406b778f2108f4b8fd17d652d888c7c10c41486e36cd